Key facts
- Novilytic’s last known valuation is $12.5M (Mar 2025).
- It has raised $10.9M across 2 recorded rounds; the latest was Seed Round ($531K) in Dec 2025.
- Notable investors include Elevate Ventures, BioTools Innovator, Purdue Ventures.
- Novilytic has filed 2 Form Ds with the SEC since 2021, most recently Dec 2025 ($531K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Novilytic
Funding rounds
2 roundsAbout Novilytic
Developer of a nanotechnology designed to monitor the quality of lifesaving medicines in biopharmaceutical manufacturing. The company offers a patented Proteometer consumables platform that enables real-time bioreactor analysis without complex preparation or multiple instruments, enabling pharmaceutical companies to streamline development, clone selection, and process research while accelerating production workflows.
- Sector
- Healthcare
- HQ
- West Lafayette, IN, United States
- Founded
- 2013
- Employees
- 15
- Website
- novilytic.com/
- Ownership
- Privately Held (backing)
Novilytic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novilytic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novilytic in its N-PORT filings yet. We sweep new filings monthly.